Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen in HIV-1 infection: a guide to its use in the EU

Abstract

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (tenofovir DF) [Eviplera Ò (EU); Complera Ò (USA)] is a convenient and effective addition to the other single-tablet regimens currently available for the treatment of HIV-1 infection. Once-daily emtricitabine/rilpivirine/tenofovir DF was noninferior to once-daily emtricitabine/efavirenz/tenofovir DF in establishing virological suppression in treatmentnaïve adults. Switching to the once-daily single tablet maintained virological suppression and was noninferior to remaining on a more complex multiple-tablet regimen in treatment-experienced patients already virologically suppressed with an antiretroviral regimen and without prior virological failure. Emtricitabine/rilpivirine/tenofovir DF was generally well tolerated, with a more favourable overall tolerability profile than emtricitabine/efavirenz/tenofovir DF.